Download
s40262-021-01041-x.pdf 3,76MB
WeightNameValue
1000 Titel
  • Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
1000 Autor/in
  1. Kneller, Lisa Alina |
  2. Zubiaur, Pablo |
  3. Koller, Dora |
  4. Abad-Santos, Francisco |
  5. Hempel, Georg |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-14
1000 Erschienen in
1000 Quellenangabe
  • 60(12):1569-1582
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40262-021-01041-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613074/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background and objectives!#!Aripiprazole is an atypical antipsychotic drug that is metabolized by cytochrome P450 (CYP) 2D6 and CYP3A4, which mainly form its active metabolite dehydro-aripiprazole. Because of the genetic polymorphism of CYP2D6, plasma concentrations are highly variable between different phenotypes. In this study, phenotype-related physiologically based pharmacokinetic models were developed and evaluated to suggest phenotype-guided dose adjustments.!##!Methods!#!Physiologically based pharmacokinetic models for single dose (oral and orodispersible formulation), multiple dose, and steady-state condition were built using trial data from genotyped healthy volunteers. Based on evaluated models, dose adjustments were simulated to compensate for genetically caused differences.!##!Results!#!Physiologically based pharmacokinetic models were able to accurately predict the pharmacokinetics of aripiprazole and dehydro-aripiprazole according to CYP2D6 phenotypes, illustrated by a minimal bias and a good precision. For single-dose administration, 92.5% (oral formulation) and 79.3% (orodispersible formulation) of the plasma concentrations of aripiprazole were within the 1.25-fold error range. In addition, physiologically based pharmacokinetic steady-state simulations demonstrate that the daily dose for poor metabolizer should be adjusted, resulting in a maximum recommended dose of 10 mg, but no adjustment is necessary for intermediate and ultra-rapid metabolizers.!##!Conclusions!#!In clinical practice, CYP2D6 genotyping in combination with therapeutic drug monitoring should be considered to personalize aripiprazole dosing, especially in CYP2D6 poor metabolizers, to ensure therapy effectiveness and safety.
1000 Sacherschließung
lokal Antipsychotic Agents [MeSH]
lokal Aripiprazole [MeSH]
lokal Pharmacology/Toxicology
lokal Piperazines [MeSH]
lokal Quinolones [MeSH]
lokal Cytochrome P-450 CYP2D6/genetics [MeSH]
lokal Humans [MeSH]
lokal Genotype [MeSH]
lokal Original Research Article
lokal Phenotype [MeSH]
lokal Internal Medicine
lokal Pharmacotherapy
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S25lbGxlciwgTGlzYSBBbGluYQ==|https://frl.publisso.de/adhoc/uri/WnViaWF1ciwgUGFibG8=|https://frl.publisso.de/adhoc/uri/S29sbGVyLCBEb3Jh|https://frl.publisso.de/adhoc/uri/QWJhZC1TYW50b3MsIEZyYW5jaXNjbw==|https://orcid.org/0000-0002-5790-6423
1000 Hinweis
  • DeepGreen-ID: 2255c591cc8b47d7b0cf05f866f45c16 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464933.rdf
1000 Erstellt am 2023-11-16T08:36:37.546+0100
1000 Erstellt von 322
1000 beschreibt frl:6464933
1000 Zuletzt bearbeitet 2023-12-01T01:10:33.883+0100
1000 Objekt bearb. Fri Dec 01 01:10:33 CET 2023
1000 Vgl. frl:6464933
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464933 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source